Tumor microenvironment protease (TME protease)

Tumor microenvironment (TME) proteases represent a diverse class of enzymes, including matrix metalloproteinases (MMPs), cysteine cathepsins, and serine proteases, that are frequently overexpressed or aberrantly active in the stroma surrounding solid tumors (1.1.1, 1.3.1). These enzymes are critical drivers of malignancy, facilitating extracellular matrix (ECM) degradation, which allows for tumor cell invasion, migration, and metastasis (1.2.1, 1.3.2). Beyond structural remodeling, TME proteases also regulate the bioavailability and activation of various growth factors, cytokines, and chemokines, thereby promoting angiogenesis and an immunosuppressive environment (1.3.2, 1.5.1). Historically, broad-spectrum protease inhibitors, particularly those targeting MMPs, faced significant clinical setbacks due to poor selectivity and dose-limiting toxicities such as musculoskeletal syndrome (1.2.1, 1.5.1). Modern therapeutic approaches have shifted toward utilizing the high local activity of these proteases to trigger the site-specific activation of 'probodies' and protease-activatable prodrugs (1.3.4, 1.4.2). This strategy aims to concentrate the therapeutic effect within the tumor while sparing healthy tissues from systemic toxicity, making TME proteases essential tools for precision drug delivery in oncology (1.5.2).

Other names

Cancer-associated proteasesExtracellular proteasesTumor-associated peptidasesTME-associated proteasesTumor-secreted proteases

Drugs targeting tumor microenvironment proteases primarily function through two distinct mechanisms: the direct inhibition of enzymatic activity to prevent extracellular matrix degradation and signaling, or the utilization of high local protease concentrations to proteolytically activate masked prodrugs, antibody-drug conjugates, or probodies specifically within the tumor site (1.2.1, 1.3.4, 1.4.2).